AstraZeneca, Daiichi Sankyo’s Enhertu claims another Phase 3 victory in HER2-low breast cancer
Enhertu notched another win for AstraZeneca and Daiichi Sankyo that could see uptake moved slightly earlier in a specific subset of breast cancer patients.
The Phase 3 DESTINY-Breast06 study set Enhertu against chemotherapy. The ADC hit the progression-free survival primary endpoint in the primary trial population of HR-positive breast cancer patients who are low on HER2, or the human epidermal growth factor receptor 2, and have gone through one or more lines of endocrine therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
